Search

Displaying results 1721 - 1730 of 7687 in total
  1. Drug

    PSN9301

    go.drugbank.com/drugs/DB05001
    Experimental

    PSN9301 is an oral small molecule inhibitor of Dipeptidyl Peptidase IV (DP-IV), being developed for the treatment of type 2 diabetes. … PSN9301 has a very rapid onset and a relatively short duration of action, and available pre-clinical and clinical data indicate that it may be an ideal product candidate for meal-related dosing.

  2. Drug

    Gepirone

    go.drugbank.com/drugs/DB12184
    Approved

    Although earlier clinical trials showed promising results for gepirone, its formulation as an immediate-release tablet necessitates frequent administration due to the short half-lives. … [A261670,A261675,A182315] Gepirone was approved by the FDA on September 28, 2023, under the brand name EXXUA for the treatment of adults with major depressive disorder.

  3. Drug

    Pegfilgrastim

    go.drugbank.com/drugs/DB00019
    ApprovedInvestigational

    There are several pegfilgrastim biosimilars (Fulphila, Pelgraz or Lapelga, Pelmeg, Udenyca, Ziextenzo, Grasustek, Fylnetra, Stimufend) by Health Canada, European Union (EU), and FDA that are approved to … [A187607] First developed by Amgen, pegfilgrastim was initially approved by the FDA in 2002 and marketed as Neulasta. It is typically administered via a subcutaneous injection.

  4. Drug

    Histidine

    go.drugbank.com/drugs/DB00117
    ApprovedInvestigationalNutraceutical

    An essential amino acid that is required for the production of histamine.

    Mixtures: SOLUCION DP-AMINE, TRAVASOL PLUS 15% LIBRE DE BISULFITO
  5. Drug

    Reserpine

    go.drugbank.com/drugs/DB00206
    ApprovedWithdrawn

    The FDA withdrew its approval for the use of all oral dosage form drug products containing more than 1 mg of reserpine.[L43942] … It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.

  6. Drug

    Elafibranor

    go.drugbank.com/drugs/DB05187
    ApprovedInvestigational

    [L50768] On June 10, 2024, elafibranor was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis (PBC).

  7. Drug

    Axicabtagene ciloleucel

    go.drugbank.com/drugs/DB13915
    ApprovedInvestigational

    [A216163] Axicabtagene ciloleucel was approved by the FDA on October 18th, 2017. … can produce cytokines that efficiently kill leukemic cells _in vitro_.

    Synonyms: Autologous T cells transduced with retroviral vector encoding an anti-CD-19 CD28/CD3-zeta chimeric antigen receptor
  8. Drug

    Alverine

    go.drugbank.com/drugs/DB01616
    ApprovedInvestigationalWithdrawn

    It can also be used to help relieve period pain.

    Synonyms: Di(phenylpropyl)ethylamine
  9. Drug

    NADH

    go.drugbank.com/drugs/DB00157
    ApprovedNutraceutical

    It forms NADP with the addition of a phosphate group to the 2' position of the adenosyl nucleotide through an ester linkage. (Dorland, 27th ed) … It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH).

  10. Drug

    Pancrelipase protease

    go.drugbank.com/drugs/DB11066
    ApprovedInvestigational

    [A32742, L2543] The pancrelipase mixture, including pancrelipase protease, was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.[L2510]

    Mixtures: KREON MIKRO 5000 IU MINIMIKROSFER,